Zomedica Corp. (ZOM) Q3 2024 Earnings Call Transcript Summary
Zomedica Corp. (ZOM) Q3 2024 Earnings Call Transcript Summary
Net loss for the quarter was $6.7 million, with a non-GAAP The following is a summary of the Zomedica Corp. (ZOM) Q3 2024 Earnings Call Transcript:
以下是Zomedica Corp.（ZOM）2024年第三季度業績電話會議記錄的摘要：
Financial Performance:
財務業績：
Zomedica reported Q3 2024 revenue of $7 million, representing a 10.2% increase year-over-year.
Gross margin for the quarter stood at 72.3%, slightly above the company's target range of 65% to 70%.
Net loss for the quarter was $6.7 million, with a non-GAAP EBITDA loss of approximately $4.8 million.
Operating expenses for Q3 totaled $12.5 million, a 21% increase over the previous year, but a reduction of $900,000 from Q2 2024.
Zomedica報告稱，2024年第三季度收入爲700萬美元，同比增長10.2％。
該季度的毛利率爲72.3％，略高於公司65％至70％的目標區間。
該季度的淨虧損爲670萬美元，非公認會計准則息稅折舊攤銷前利潤虧損約爲480萬美元。
第三季度的運營支出總額爲1,250萬美元，比上年增長21％，但比2024年第二季度減少了90萬美元。
Business Progress:
業務進展：
Zomedica's commercial strategy drove a 24.5% increase in PulseVet revenue, with new system sales rebounding strongly.
Diagnostics segment revenue improved by 38% year-over-year, significantly driven by an 80% growth in TRUFORMA platform utilization.
International expansion included new strategic partnerships and regulatory approvals, enhancing access in the EU, Middle East, Egypt, India, and Central America.
Development of AI capabilities and other innovations across diagnostic and therapeutic product lines continued, poised for further launches.
Zomedica的商業戰略推動PulseVet收入增長了24.5％，新系統的銷售強勁反彈。
診斷板塊收入同比增長38％，這在很大程度上受TRUFORMA平台利用率增長80％的推動。
國際擴張包括新的戰略伙伴關係和監管部門的批准，從而增強了在歐盟、中東、埃及、印度和中美洲的准入。
診斷和治療產品系列的人工智能能力和其他創新仍在繼續，有望進一步推出。
Opportunities:
機會：
Expansion into international markets is set to be a significant growth driver, with new partnerships increasing global footprint.
Existing and upcoming product innovations provide further opportunities for growth in both diagnostics and therapeutic segments.
向國際市場的擴張將成爲重要的增長動力，新的合作伙伴關係將擴大全球足跡。
現有和即將推出的產品創新爲診斷和治療領域的增長提供了進一步的機會。
Risks:
風險：
As product penetration deepens, maintaining market expansion pace may challenge operational capacities despite positive momentum.
Economic influences on capital expenditures in the veterinary sector pose potential risks, with interest rates affecting customer purchasing behavior.
隨着產品滲透率的加深，儘管勢頭良好，但保持市場擴張步伐可能會對運營能力構成挑戰。
對獸醫行業資本支出的經濟影響構成潛在風險，利率會影響客戶的購買行爲。
Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
小貼士：本文由 AI 生成。無法完全保證內容的準確性。如需更全面的詳情，請訪問投資者關係網站。本文僅供投資者參考，不提供任何指導或建議建議。
